We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer to Change Chantix Label to Show Cardiovascular Risks
Pfizer to Change Chantix Label to Show Cardiovascular Risks
July 29, 2011
The FDA is asking Pfizer to update the label of its popular quit-smoking drug Chantix to include additional safety risks, including heart attack, for patients with cardiovascular disease.